Colorectal Cancer Market is valued at USD 11.83 Billion in 2021 and is expected to reach USD 16.21 Billion by 2028 with a CAGR of 5.40% over the forecast period.
The Detailed Market intelligence report on the Colorectal Cancer Market applies the most effective of each primary and secondary analysis to weighs upon the competitive landscape and also the outstanding market players expected to dominate Colorectal Cancer Market place for the forecast 2022– 2028.
Rising acceptance of the western diet which is low in fiber and high in fat is predicted to power the development of colorectal cancer market over the coming period.
Colorectal cancer is cancer that begins in the rectum or colon. The rectum and the colon are parts of the big intestine, which is the digestive system of the body’s lower part. The colon absorbs nutrients and water from the food and amasses waste matter. Stool shifts into the rectum from the colon before it gets out of the body. Colorectal cancer often starts as a development dubbed as a polyp, which night form on the interior wall of the rectum or colon. Some polyps turn out to be cancer eventually. Finding and eliminating polyps can stop colorectal cancer. At the time of digestion, food shifts via the small intestine and stomach into the colon. Most colorectal cancers are adenocarcinomas. Some of the usually witnessed signs of colorectal cancer are blood in the fatigue, weight loss, stool, and uneven bowel movements. Colorectal cancer is an outcome of uncontrolled cell development that takes place in the colon, appendix, and the rectum region.
On the basis of treatment option, colorectal cancer is divided as radiation therapy, surgery, targeted therapy, and chemotherapy. Surgery stays the most effectual option for colorectal cancer. Radiation therapy lowers the odds of cancer recurrence or distribution and is effectual as adjuvant or additional therapy either after or before surgery. The section is predicted to develop swiftly over the coming period owing to increasing awareness and rising technical enhancements.
|Historical data||2018 - 2021|
|Forecast Period||2022 - 2028|
|Market Size in 2021:||USD 11.83 Billion|
|Base year considered||2021|
|Forecast Period CAGR %:||
|Market Size Expected in 2028:||USD 16.21 Billion|
|Tables, Charts & Figures:||175|
|Colorectal Cancer Companies||Beckman Coulter, Abbott Laboratories, Companion DX, Clinical Genomics, Epigenomics AG, EDP Biotech, Novigenix, F. Hoffmann-La Roche AG, Siemens Healthineers, Quest Diagnostics, VolitionRX, others|
|Segments Covered||By Therapies & Drugs, Testing & Diagnosis, By Procedures, By Product, By Application|
|Regional Analysis||North America, U.S., Mexico, Canada, Europe, UK, France, Germany, Italy, Asia Pacific, China, Japan, India, Southeast Asia, South America, Brazil, Argentina, Columbia, The Middle East and Africa, GCC, Africa, Rest of the Middle East and Africa|
By Therapies & Drugs
By Testing & Diagnosis
The major players in the global colorectal cancer market are,
Rising Acceptance of Western Diet Predicted To Power The Development Of Colorectal Cancer Market Over The Coming Period
Rising employment of targeted and biologics therapies will hinder the market for bladder cancer drugs. Biologic therapy employs immune system of a body to deal with cancer instead of chemical drugs which lowers the immune power of the body. Targeted therapies ban the spreading and development of colorectal cancer even in stage IV where chemical medicines are ineffective.
The colorectal cancer market is managed by regulatory bodies laid down by organizes such as American Society of Clinical Oncology (ASCO), European Medicines Agency (EMA), US Food and Administration Agency (FDA), and others. For example, FDA's suggestion for colorectal cancer drugs sector in the form of rules are cited inside the Code for Federal Regulations’ (CFR) under part 312 title number 21, that has sub-parts from A to I.
The United States is Predicted to Retain Biggest Market Share During the Coming Period
Area-wise, the US has holds the biggest share of the market regarding revenue and demand. Almost 95,520 new colon cancer cases and 39,910 new rectal cancer cases in 2017 were reported in the US on the basis of the forecast by the American Cancer Society. These forecasts show that colorectal cancer is rising its occurrence in the US, which is powering the development of the market. The Asia Pacific is also predicted to see a solid development pattern in the years to come, with India and China displaying rapid development. In 2015, Roche inked a deal in Shenzhen City with an insurance firm. The Chinese population was amongst the first few to accept Avastin for reimbursement. This is predicted to elevate access in China to colorectal cancer therapeutics.
Middle East and Africa